To The Moon

With tech companies raking in profits and the Fed looking to cut rates, $Goldman Sachs(GS)$ predicts that stock buybacks in the US will soar to over $1 trillion for the first time in 2025.Goldman Sachs said it expects share buybacks by $S&P 500(.SPX)$ companies to rise 16% to $1.08 trillion in 2025, and 13% to $925 billion in 2024.Earnings growth is the main driver behind these insane buybacks, companies tend to buy back shares when they're confident about the future and think their stock is undervalued.The benchmark S&P 500 index is up 7% this year, nearing all-time highs, thanks to the AI hype and bets on lower US interest rates. Some big banks think the index has even more room to run.Goldman str

Despite the challenging global macroeconomic environment, $Illumina(ILMN)$, the leader in genomic sequencing technology, released its Q1 2024 earnings report, and it exceeded analysts' expectations!Illumina, the global powerhouse in genomic sequencing and chip technology, aims to "improve human health with the power of genetics." Its core business revolves around developing and manufacturing cutting-edge sequencing and analysis systems, essential tools for both research and clinical applications. To stay ahead, they're constantly investing in R&D, upgrading their technology platforms, expanding their market reach, improving accessibility, and building strategic partnerships.Sure, macroeconomic factors dragged down Illumina's revenue a bit in Q

$Inovio Pharmaceuticals(INO)$ , a biotech company with a market cap of just $305 million, was once part of the coronavirus vaccine development race but unfortunately didn't make it. Their market cap suffered a significant drop because of that. But don't count INO out yet! Their stock has soared 96% this year.INO specializes in DNA-based drugs. They use a unique platform to produce DNA plasmid molecules and inject them into patients to generate antibodies against specific diseases. While they have 8 clinical trial projects, most haven't advanced to phase 3, like their abandoned COVID-19 vaccine INO-4800 and HPV cancer vaccine VGX-3100.But here's some good news! Their potential treatment for recurrent respiratory papillomatosis (RRP) related to HPV t

Some seasoned investment gurus are saying there's still a lot of room for the US stock market to drop. But hey, if the market goes into a tailspin, it might just be the silver lining for these electric vehicle charging stocks like $ChargePoint Holdings Inc.(CHPT)$ $Blink Charging(BLNK)$ $EVgo Inc​.(EVGO)$. Their valuations are likely to hit those irresistibly low buy zones, giving investors a chance to get in on the action at rock-bottom prices.1. ChargePoint $ChargePoint Holdings Inc.(CHPT)$ is one of the world's largest EV charging networks. Its stock price has taken a tumble recently, bringing its price-to-sales rati

With Rinvoq and Skyrizi, these new anti-inflammatory drugs, taking over the throne from Humira, $AbbVie(ABBV)$ has increased its full-year profit forecast in 2024.AbbVie now expects adjusted earnings per share to range from $11.13 to $11.33, exceeding the previous high of $11.17 per share, according to a statement Friday.Abbvie shares fell 1.3% at the start of trading in New York. As of Thursday's close, the stock had risen 8%. The company has been working to fill the void left by Humira after it lost patent protection last year and cheaper biosimilars began eating into market share.Abbvie's new biologic drugs like Skyrizi and Rinvoq have been helping to offset the impact of declining Humira sales. And the company's recent deals in cancer and neur

A lot of quality healthcare stocks offer investors long-term stability, good growth prospects, and even dividends. But $Bristol-Myers Squibb(BMY)$ doesn't quite meet all those criteria.This healthcare stock has been facing some challenges recently, but now it might just be seeing the light at the end of the tunnel. With its undervalued status, this could be a long-term buying opportunity for contrarian investors.The stock has fallen 30% in the past 12 months, thanks to its roughly $37 billion in long-term debt on the company's books in a high-interest rate environment, and the loss of patent protection for Eliquis, Opdivo and Revlimid in the coming years as sales slump. In addition, BMY's revenue fell 3% last year to $45 billion, the second straigh

With the continuous advancement of AI technology, more innovative medical applications will inevitably emerge in the future. $Recursion Pharmaceuticals, Inc.(RXRX)$ partnered with chipmaker $NVIDIA Corp(NVDA)$ in 2023 to conduct AI-led drug development, and the company's stock surged after the announcement.On Wednesday, $Moderna, Inc.(MRNA)$ , the developer of the COVID-19 vaccine, announced a partnership with OpenAI to deploy the AI company's ChatGPT Enterprise in its business to accelerate drug development.According to the collaboration agreement, approximately 3,000 Moderna employees will have access to ChatGPT Enterprise, built on OpenAI's cutting-edge langua

These three stocks have already made a ton of millionaires, and they're probably going to make even more! So, Is it too late to add them to the portfolio?1.Constellation Software $Constellation Software, Inc.(CNSWF)$ is a powerhouse in acquiring leading software and services in the market. Their revenue has skyrocketed to $8 billion in 2023. With a strategy that combines organic growth and acquisitions, they've transformed into an international professional solutions provider. From 2007 to 2023, Constellation's stock price has seen an equally impressive transformation. Shares have soared from around $23 to the current $3,720, an increase of more than 16,000%. Obviously, many millionaires have been born.2.Shopify

AI stocks are stealing the spotlight from other emerging technologies, including quantum computing stocks. But don't worry, the explosion of quantum computing stocks in the US market is just a matter of time. According to BCC Research, this market is expected to grow at a whopping 48.1% CAGR from 2022 to 2028, reaching a whopping $6.5 billion!Here are three quantum computing stocks in the US market that combine stability with upside potential:1.IBM $IBM(IBM)$ is a pioneer in the quantum computing space. IBM Quantum is a world leader in building quantum hardware and plays a crucial role in commercializing this technology. Their goal? To effectively scale quantum computing to solve complex problems, reduce error rates, and develop industry-specific a

The bull market in the US stock market is essentially a bull market for these seven giants of tech with huge market caps. But the biggest investors in the US, those ginormous fund management companies, can't pile on the "Magnificent Seven" because they're bound by the rules of "diversification".However, these funds are willing to ditch their "diversification" status and pump up their holdings in the "Magnificent Seven", unleashing a fresh wave of investment funds flooding into these behemoth stocks. $HSBC Holdings PLC(HSBC)$ did some digging and found that almost every US fund manager- those with assets under management (AUM) of more than $1.9 trillion - underweights the "Magnificent Seven". Specifically, while the "Magnificent Seven" -